CLINICAL TRIALS PROFILE FOR DORIPENEM

All Clinical Trials for DORIPENEM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00210938 ↗	Doripenem in the Treatment of Complicated Intra-Abdominal Infections	Completed	Peninsula Pharmaceuticals, Inc.	Phase 3	2004-03-01	The purpose of this study is to compare the clinical response rates of doripenem versus a comparator antibiotic in treatment of hospitalized patients with complicated intra-abdominal infections.
NCT00210938 ↗	Doripenem in the Treatment of Complicated Intra-Abdominal Infections	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2004-03-01	The purpose of this study is to compare the clinical response rates of doripenem versus a comparator antibiotic in treatment of hospitalized patients with complicated intra-abdominal infections.
NCT00210990 ↗	Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis	Completed	Peninsula Pharmaceuticals, Inc.	Phase 3	2004-03-01	The purpose of this study is to assess the microbiological cure rate of doripenem in the treatment of patients with complicated urinary tract infection or pyelonephritis. The study will also characterize the safety and tolerability of treatment with doripenem in patients with complicated urinary tract infection or pyelonephritis.
NCT00210990 ↗	Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2004-03-01	The purpose of this study is to assess the microbiological cure rate of doripenem in the treatment of patients with complicated urinary tract infection or pyelonephritis. The study will also characterize the safety and tolerability of treatment with doripenem in patients with complicated urinary tract infection or pyelonephritis.
NCT00211003 ↗	Doripenem in the Treatment of Hospital-Acquired Pneumonia	Completed	Peninsula Pharmaceuticals, Inc.	Phase 3	2004-05-01	The purpose of this study is to compare the safety and effectiveness of doripenem in patients with hospital-acquired pneumonia (HAP).
NCT00211003 ↗	Doripenem in the Treatment of Hospital-Acquired Pneumonia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2004-05-01	The purpose of this study is to compare the safety and effectiveness of doripenem in patients with hospital-acquired pneumonia (HAP).
NCT00211016 ↗	Doripenem in the Treatment of Ventilator-Associated Pneumonia	Completed	Peninsula Pharmaceuticals, Inc.	Phase 3	2004-08-01	The purpose of this study is to compare the clinical response rate of doripenem versus comparator in patients with ventilator-associated pneumonia (VAP).

Clinical Trial Conditions for DORIPENEM

Condition Name

Condition Name for DORIPENEM
Intervention	Trials
Urinary Tract Infections	5
Ventilator-associated Pneumonia	5
Pneumonia	5
Pneumonia, Ventilator-Associated	4

Condition MeSH

Condition MeSH for DORIPENEM
Intervention	Trials
Infections	15
Infection	15
Communicable Diseases	13
Pneumonia	12

Clinical Trial Locations for DORIPENEM

Trials by Country

Trials by Country for DORIPENEM
Location	Trials
United States	67
Argentina	7
Ukraine	6
Mexico	5
Russian Federation	5

Trials by US State

Trials by US State for DORIPENEM
Location	Trials
Ohio	7
Michigan	7
California	6
Arkansas	4
District of Columbia	4

Clinical Trial Progress for DORIPENEM

Clinical Trial Phase

Clinical Trial Phase for DORIPENEM
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	13
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for DORIPENEM
Clinical Trial Phase	Trials
Completed	22
Terminated	5
Unknown status	1

Clinical Trial Sponsors for DORIPENEM

Sponsor Name

Sponsor Name for DORIPENEM
Sponsor	Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	8
Peninsula Pharmaceuticals, Inc.	6
Janssen Research & Development, LLC	5

Sponsor Type

Sponsor Type for DORIPENEM
Sponsor	Trials
Industry	31
Other	16